Deep Track Capital, LP Verve Therapeutics, Inc. Transaction History

Deep Track Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $12.1 Million - $32.2 Million	775,000 New	775,000 $26.6 Million
Q2 2022 Aug 12, 2022	SELL	$11.14 - $23.17 $1.14 Million - $2.37 Million	-102,342 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$20.92 - $39.36 $8.32 Million - $15.7 Million	-397,658 Reduced 79.53%	102,342 $2.34 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $16 Million - $27.4 Million	500,000 New	500,000 $18.4 Million

181

73.4M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $489M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Deep Track Capital, LP with notifications on news.